CD38 and plasma cell myeloma: Isatuximab, a chimeric IgG monoclonal antibody targeting a unique epitope on CD38, exerts anti-myeloma effects through mechanisms including antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, direct induction of apoptosis, and inhibition of CD38 enzyme activity [83, 84].